Should I buy or sell DarioHealth stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRIO shares. View DRIO analyst ratings or view top-rated stocks .

What is DarioHealth's stock price target for 2024?

2 Wall Street analysts have issued twelve-month target prices for DarioHealth's stock. Their DRIO share price targets range from $4.00 to $8.00. On average, they predict the company's stock price to reach $5.37 in the next year. This suggests a possible upside of 354.8% from the stock's current price. View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts .

How have DRIO shares performed in 2024?

DarioHealth's stock was trading at $1.72 at the beginning of 2024. Since then, DRIO stock has decreased by 31.4% and is now trading at $1.18. View the best growth stocks for 2024 here .

When is DarioHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DRIO earnings forecast .

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by $0.24. The company earned $5.63 million during the quarter, compared to the consensus estimate of $5.95 million. DarioHealth had a negative net margin of 165.96% and a negative trailing twelve-month return on equity of 48.84%. During the same quarter in the previous year, the company earned ($0.71) EPS.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS) , Vascular Biogenics (VBLT) , Nano Dimension (NNDM) , Pluristem Therapeutics (PSTI) , NVIDIA (NVDA) , AbbVie (ABBV) , Gilead Sciences (GILD) , ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL) .

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does DarioHealth have any subsidiaries?

The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd.. Read More

NASDAQ:DRIO

DarioHealth (DRIO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free DRIO Stock Alerts

$1.16

+0.01 (+0.87%)

(As of 05:21 PM ET)

Compare

Today's Range: $1.11
▼
$1.19
50-Day Range: $1.14
▼
$2.55
52-Week Range: $0.68
▼
$4.58

Volume: 49,509 shs
Average Volume: 135,979 shs
Market Capitalization: $34.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.37

Get DarioHealth alerts:

DarioHealth MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 354.8% Upside
$5.37 Price Target
Short Interest: Bearish
4.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.20) to ($1.61) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.23 out of 5 stars

Medical Sector

750th out of 918 stocks

Surgical & Medical Instruments Industry

77th out of 96 stocks

3.5

Analyst's Opinion

Consensus Rating
DarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
DarioHealth has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.62% of the outstanding shares of DarioHealth have been sold short.
Short Interest Ratio / Days to Cover
DarioHealth has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in DarioHealth has recently increased by 1.49%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
DarioHealth does not currently pay a dividend.
Dividend Growth
DarioHealth does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DRIO.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for DarioHealth this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for DRIO on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added DarioHealth to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DarioHealth insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.10% of the stock of DarioHealth is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.39% of the stock of DarioHealth is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for DarioHealth are expected to grow in the coming year, from ($2.20) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DarioHealth is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DarioHealth is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DarioHealth has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About DarioHealth Stock (NASDAQ:DRIO)

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DRIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DRIO Stock News Headlines

April 18, 2024 | prnewswire.com

Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution

April 17, 2024 | money.usnews.com

DarioHealth Corp

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 15, 2024 | americanbankingnews.com

DarioHealth (NASDAQ:DRIO) versus Star Equity (NASDAQ:STRRP) Head-To-Head Contrast

April 10, 2024 | prnewswire.com

Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

April 3, 2024 | benzinga.com

DarioHealth Stock (NASDAQ:DRIO), Analyst Ratings, Price Targets, Predictions

April 2, 2024 | prnewswire.com

Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health

April 1, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 30, 2024 | seekingalpha.com

DarioHealth Corp. (DRIO) Q4 2023 Earnings Call Transcript

March 28, 2024 | finanznachrichten.de

DarioHealth Corp.: DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

March 28, 2024 | markets.businessinsider.com

DarioHealth earnings preview: what to expect

March 28, 2024 | investorplace.com

DRIO Stock Earnings: DarioHealth Beats EPS, Beats Revenue for Q4 2023

March 28, 2024 | finance.yahoo.com

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

March 21, 2024 | prnewswire.com

DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH

March 15, 2024 | finance.yahoo.com

DRIO Apr 2024 5.000 put

March 12, 2024 | prnewswire.com

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

March 7, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR)

February 28, 2024 | prnewswire.com

DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE

February 28, 2024 | prnewswire.com

DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE

February 21, 2024 | ca.finance.yahoo.com

DarioHealth Corp. (DRIO)

February 21, 2024 | tmcnet.com

Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

February 21, 2024 | msn.com

Dario buys Twill to create digital health platform across most prevalent chronic conditions

February 21, 2024 | prnewswire.com

Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

February 6, 2024 | benzinga.com

DarioHealth Stock (NASDAQ:DRIO), Short Interest Report

January 18, 2024 | msn.com

Cano Health, DarioHealth among healthcare movers

January 11, 2024 | finance.yahoo.com

DarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five years

See More Headlines

Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:DRIO
CUSIP: N/A
CIK: 1533998
Web: www.mydario.com
Phone: (833) 914-3796
Fax: 972-4770-4059
Employees: 276
Year Founded: 2011

Price Target and Rating

Average Stock Price Target: $5.37
High Stock Price Target: $8.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +362.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,430,000.00
Net Margins: -165.96%
Pretax Margin: -291.68%
Return on Equity: -48.84%
Return on Assets: -31.56%

Debt

Debt-to-Equity Ratio: 0.42
Current Ratio: 3.79
Quick Ratio: 3.38

Sales & Book Value

Annual Sales: $20.35 million
Price / Sales: 1.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.14 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 29,440,000
Free Float: 26,469,000
Market Cap: $34.15 million
Optionable: Optionable
Beta: 1.66

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Erez Raphael (Age 51)
CEO & Director
Comp: $722.19k
Mr. Richard A. Anderson (Age 55)
President
Comp: $536.65k
Mr. Zvi Ben David CPA (Age 63)
CFO, Treasurer & Secretary
Comp: $342.58k
Dov Oppenheim
Co-Founder & Production Chief
Mr. Tomer Ben-Kiki (Age 53)
Chief Operating Officer
Josh Fischer
Senior Vice President of Operations & Compliance
Claudia Levi
Content & Communications Manager
Mary Mooney
Vice President of Marketing
Limor Drezner
Chief People Officer
Mr. Jean Christophe Muyl
Head of Commercialization North America

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DRIO Stock Analysis - Frequently Asked Questions

Should I buy or sell DarioHealth stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings or view top-rated stocks.
What is DarioHealth's stock price target for 2024?: 2 Wall Street analysts have issued twelve-month target prices for DarioHealth's stock. Their DRIO share price targets range from $4.00 to $8.00. On average, they predict the company's stock price to reach $5.37 in the next year. This suggests a possible upside of 354.8% from the stock's current price.
View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts.
How have DRIO shares performed in 2024?: DarioHealth's stock was trading at $1.72 at the beginning of 2024. Since then, DRIO stock has decreased by 31.4% and is now trading at $1.18.
View the best growth stocks for 2024 here.
When is DarioHealth's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DRIO earnings forecast.

How were DarioHealth's earnings last quarter?: DarioHealth Corp. (NASDAQ:DRIO) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by $0.24. The company earned $5.63 million during the quarter, compared to the consensus estimate of $5.95 million. DarioHealth had a negative net margin of 165.96% and a negative trailing twelve-month return on equity of 48.84%. During the same quarter in the previous year, the company earned ($0.71) EPS.
What other stocks do shareholders of DarioHealth own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).
How do I buy shares of DarioHealth?: Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does DarioHealth have any subsidiaries?: The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..
Read More

This page (NASDAQ:DRIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial